

Claims

1. Use of combination preparations that contain
- a natural or synthetic androgen
 - and a component from the group of gestagens, antigestagens, antiestrogens, GnRH analogs, testosterone-5 α -reductase inhibitors, α -andreno-receptor blockers or phosphodiesterase inhibitors
- for compensating for an absolute or relative testosterone deficiency with simultaneous prophylaxis for the development of a benign prostatic hyperplasia (BPH) or a prostate cancer.
2. Use of combination preparations according to claim 1, characterized in that the natural androgen component is testosterone, testosterone undecanoate, dehydroepiandrosterone, dehydroepiandrosterone sulfate, testosterone propionate, testosterone enanthate, testosterone buciclate, testosterone cypionate or androstene dione.
3. Use of combination preparations according to claim 1, wherein the synthetic androgen component is 17-methyltestosterone, fluoxymesterone, danazol, mesterolone, nandrolone decanoate, nandrolone phenylpropionate, oxandrolone, oxymetholone, or stanazolol.
4. Use of combination preparations according to claim 1, wherein the gestagen component is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, norethisterone acetate, levonorgestrel or progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone

09/10/2011 10:10:11

Sub
E

acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

5. Use of the combination preparations according to claim 1, wherein the antigestagen component is

4-[17 β -Hydroxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime (J 912);

4-[-17 β -methoxy-17 α -(methoxymethyl)-3-oxo-estra-4,9-dien-11 β -yl]-benzaldehyde-1(E)-{O-[(ethylthio)carbonyl]}-oxime (J 1042);

4-[9 α ,10 α -epoxy-17 β -hydroxy-17 α -(methoxymethyl)-3-oxo-estra-4-en-11 β -yl]-benzaldehyde-1(E)-oxime (J 1116);

4-[17 β -methoxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-oxime (J 867);

4-[17 β -hydroxy-17 α -(methoxymethyl)-3oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-{O-[(N-ethyl)-carbonyl]}-oxime (J 956);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -propinyl-estra-4,9-dien-3-one (RU 38 486 - mifepristone);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 α -hydroxy-17 β -(3-hydroxypropyl)-13 α -methyl-gona-4,9-dien-3-one (ZK 98299 - onapristone);

11 β -(4-acetylphenyl)-17 β -hydroxy-17 α -propinyl-estra-4,9-dien-3-one (ZK 112993);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-(Z)-propenyl)-estra-4,9-dien-3-one (ZK 98 734 - lilopristone);

11 β -[(4-N,N-dimethylamino)-phenyl]-17 β -hydroxy-17 α -(3-hydroxy-1-(Z)-propenyl)-estra-4-en-3-one (ZK 137 316);

09719921 0015001

[Handwritten signature]
21

[Handwritten mark]
G1

11 β -[(4-N,N-dimethylamino)-phenyl]-6 β -methyl-4',5'-dihydrospiro-[estra-4,9-diene-17,2'(3'H)-furan]-3-one (ORG 31 710);

11 β -[(4-N,N-dimethylamino)-phenyl]-7 β -methyl-4',5'-dihydrospiro-[estra-4,9-diene-17,2'(3'H)-furan]-3-one (ORG 31 806);

11 β -(4-acetylphenyl)-(3'E)-ethylidene-4',5'-dihydrospiro-[estra-4,9-diene-17,2'(3H)-furan]-3-one (ORG 33 628).

6. Use of combination preparations according to claim 1, wherein the antiestrogen component is tamoxifen, raloxifene, panomifene, toremifene, iproxifene or idoxifene.

7. Use of combination preparations according to claim 1, wherein the GnRH-analog component is buserelin, goserelin, nafarelin, triptorelin or deslorelin, leuprolide or leuprolide acetate.

8. Use of combination preparations according to claim 1, wherein the antiestrogen component is tamoxifen, raloxifene, panomifene, toremifene, iproxifene or idoxifene.

9. Use of combination preparations according to claim 1, wherein the testosterone-5 α -reductase-inhibitor component is finasteride, epristeride, permixon, or turosteride.

10. Use of combination preparations according to claim 1, wherein the α -andreno-receptor-blocker component is tolazoline, phentolamine, phenoxybenzamine, alfuzosin, or prazosin.

11. Use of combination preparations according to claim 1, wherein the phosphodiesterase-inhibitor component is amrinone, milrinone, trapidil, papaverine, vesnarinone or sildenafil.

Claim 1
12. Use of a combination preparation according to at least one of claims 1 to 4, wherein it is used in the form of tablets, capsules, coated tablets, transdermal therapy systems, ampoules, suppositories, gels, ointments, nose drops, implants, pressed parts or biodegradable microspheres.

09713221 021601

Inoc 2